Partners 2020

Gold Partners

Hansa Biopharma

Hansa Biopharma is leveraging its proprietary enzyme technology platform to develop immunomodulatory treatments for rare immunoglobulin G (IgG)-mediated autoimmune conditions, transplant rejection and cancer.

The Company’s lead product candidate, imlifidase, is an antibody-cleaving enzyme being developed to enable kidney transplantation in highly sensitized patients and may be further developed for use in other organ and tissue transplantation and acute autoimmune indications. Imlifidase is currently under review for a potential marketing authorization by European Medicines Agency (EMA).

Astellas Pharma Limited

On the forefront of healthcare change, Astellas is committed to turning innovative science into medical solutions that bring value and hope to patients worldwide.

Astellas Pharma is a global pharmaceutical company with a simple vision – to produce exceptional medicines that change tomorrow for patients in need. We strive to develop therapies that are first-in-class and best-in-class. Treatments that offer patients and their doctors genuinely new options for improving care.

Silver Partners

Chiesi Limited

Chiesi Limited are an international company with a strong focus on innovative medicines in Respiratory, Neonatology, Special Care and Rare Diseases.

Transplantation is the latest therapy area for Chiesi and an area to which they are committed to developing further as part of a growing Special Care portfolio.

Chiesi Limited are proud to be a Gold Partner to The British Transplantation Society and to provide education and support to transplant specialists and patients in the UK.


Sandoz, a Novartis division, is a world leader in generic pharmaceuticals and biosimilars, finding innovative ways to make high-quality medicines affordable, without compromising on patient management.

For over 30 years, the combined Novartis organisation has been committed to the field of transplantation, bringing new treatments to market to individualise therapy and optimize patient outcomes.